Alejandro Álvarez-Quilón

This study identifies synthetic lethal interactions between cancer drivers and tractable targets using CRISPR screens and cancer dependency data, offering new drug targets for therapy.

This study identifies on-target resistance mechanisms to WRN inhibitors in MSI cancers using functional genomics and shows how to improve therapeutic durability through drug selection and combination strategies.

This study shows neuroblastoma cells are hypersensitive to PLK4 inhibitor RP-1664 due to dual mechanisms of centriole loss and amplification, leading to cell death.

The paper identifies a consensus set of 117 genes that promote survival when ATR kinase activity is suppressed, validated through CRISPR/Cas9 screens and including previously unknown modulators of ATR inhibitor response.